The publication, entitled, "AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction," appears in the peer-reviewed journal Cancer Immunology, Immunotherapy, a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy (online publication
The current report expands upon prior studies on the results of a Phase I trial of AE37 in patients with prostate cancer. AE37 is also the subject of a controlled, randomized Phase II trial to prevent recurrence in patients who have had breast cancer. That study has shown an encouraging trend toward preventing relapse, particularly in patients with low levels of HER2 expression and in triple negative patients. The search for reliable biomarkers is a key priority in the emerging field of cancer immunotherapy. The current study makes important contributions toward that aim while supplying compelling data for the further developmental of AE37.
Keywords for this news article include: Oncology, Cancer Vaccines, Biological Products,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Bently Creates Alabama Small Business Commission
- Is Alibaba's IPO Price a Fairytale?
- When to Say No to Investors, Yes to Mentors
- Los Angeles Angels Clinch Playoff Spot
- U.S. Producer Prices Held Steady in August
- Bolivar Appointed to NSHMBA National Board
- Sanctions Push Russian Ruble to Historic Low
- U.S. Tobacco Growers Lose Last of Price Supports
- Hispanic Buying Power Slow but Growing in South
- Scottish Leaders Scramble for Votes on Independence